Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial

Table 3 The study outcomes in patients randomized to placebo or rHuEPO group

	Placebo group (n = 50)	rHuEPO group (n = 50)	p value
Incidence of AKI n (%)	19 (38)	7 (14)	<0.01
eGFR > 60 mL/min/1.73 m²	6/24 (25)	1/19 (5.26)	0.11
eGFR < 60 mL/min/1.73 m²	13/26 (50)	6/31 (19.35)	<0.05
Postoperative complication:
Bleeding n (%)	2 (4)	1 (2)	0.56
Infection n (%)	4 (8)	2 (4)	0.41
Stroke n (%)	1 (2)	0 (0)	0.32
Cardiac arrhythmia n (%)	7 (14)	6 (12)	0.77
Myocardial infarction n (%)	1 (2)	0 (0)	0.32
Hemodialysis n (%)	2 (4)	0 (0)	0.16
Hospital stay and mortality
ICU stay (days)	7 ± 4	4 ± 1	<0.01
Hospital stay (days)	17 ± 9	11 ± 2	<0.01
Hospital deaths n (%)	2 (4)	0 (0)	0.16

ISSN: 1471-2369